Interferon alfa-2b biosimilar (Blau Pharmaceuticals)

干扰素α-2b生物类似药 (Blau Pharmaceuticals)

Report date: 2022/01/24 10:09:31

Base Information

Drug NameInterferon alfa-2b biosimilar (Blau Pharmaceuticals)
Drug Alias Name干扰素α-2b生物仿制药 (Blau Pharmaceuticals)
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsLymphoma, Non-HodgkinLeukemia, MyeloidLeukemia, Hairy Cell +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBlau Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesBlau Pharmaceuticals
Inactive CompaniesN/A
Active IndicationsLymphoma, Non-HodgkinLeukemia, MyeloidLeukemia, Hairy Cell +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeL03AB05
Related LinksN/A